Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient

被引：23

作者：

Karakas, Yusuf ^{[1
]}

Yuce, Deniz ^{[2
]}

Kilickap, Saadettin ^{[2
]}

机构：

[1] Hacettepe Univ, Inst Canc, Dept Med Oncol, TR-06100 Ankara, Turkey

[2] Hacettepe Univ, Inst Canc, Dept Prevent Oncol, Ankara, Turkey

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷 / 10期

关键词：

Nivolumab; Immune thrombocytopenia; Immune-related adverse effect; IMMUNOTHERAPY; MELANOMA;

D O I：

10.1159/000477968

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：621 / +

页数：2

共 8 条

[1]

Bagley S.J., 2016, Cancer Treat. Commun, V6, P20, DOI DOI 10.1016/J.CTRC.2016.02.009

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma [J].

Gordon, Ilyssa O. ;

Wade, Takisha ;

Chin, Kevin ;

Dickstein, Jerome ;

Gajewski, Thomas F. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) :1351-1353

[4] Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells [J].

Kanameishi, S. ;

Otsuka, A. ;

Nonomura, Y. ;

Fujisawa, A. ;

Endo, Y. ;

Kabashima, K. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :546-547

[5] Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes [J].

Lühder, F ;

Höglund, P ;

Allison, JP ;

Benoist, C ;

Mathis, D .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (03) :427-432

[6] Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis [J].

Wang, HB ;

Shi, FD ;

Li, HL ;

Chambers, BJ ;

Link, H ;

Ljunggren, HG .

JOURNAL OF IMMUNOLOGY, 2001, 166 (10) :6430-6436

[7] Toxicities of Immunotherapy for the Practitioner [J].

Weber, Jeffrey S. ;

Yang, James C. ;

Atkins, Michael B. ;

Disis, Mary L. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2092-U154

[8] Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014 [J].

Weide, Rudolf ;

Feiten, Stefan ;

Friesenhahn, Vera ;

Heymanns, Jochen ;

Kleboth, Kristina ;

Thomalla, Joerg ;

van Roye, Christoph ;

Koeppler, Hubert .

ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (1-2) :41-44

← 1 →